1. Home
  2. JFR vs DRTS Comparison

JFR vs DRTS Comparison

Compare JFR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Floating Rate Income Fund

JFR

Nuveen Floating Rate Income Fund

N/A

Current Price

$7.24

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

N/A

Current Price

$12.94

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JFR
DRTS
Founded
2004
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
JFR
DRTS
Price
$7.24
$12.94
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $17.80
AVG Volume (30 Days)
★ 904.7K
431.9K
Earning Date
01-01-0001
11-19-2026
Dividend Yield
★ 11.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,235.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.09
$3.43
52 Week High
$8.00
$15.79

Technical Indicators

Market Signals
Indicator
JFR
DRTS
Relative Strength Index (RSI) 45.10 42.01
Support Level $7.23 $11.24
Resistance Level $7.64 $13.95
Average True Range (ATR) 0.09 0.63
MACD 0.01 0.00
Stochastic Oscillator 44.55 42.04

Price Performance

Historical Comparison
JFR
DRTS

About JFR Nuveen Floating Rate Income Fund

Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income. The fund invests a majority of its managed assets in secured Senior Loans and unsecured Senior Loans, with an average duration of one year or less, in which unsecured Senior Loans will be, at the time of investment, investment grade quality.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: